Population Pharmacokinetics of Prolonged Infusion Meropenem in Cystic Fibrosis (CF) Children
An Open Label Study to Assess the Population Pharmacokinetics, Safety, and Practicality of Administering Meropenem as a Prolonged Infusion to Cystic Fibrosis Children Admitted With an Acute Pulmonary Exacerbation
Sponsor: Joseph Kuti
Listed as NCT01429259, this PHASE4 trial focuses on Cystic Fibrosis and Pneumonia and remains completed. Sponsored by Joseph Kuti, it has been updated 8 times since 2012, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE4
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE4
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE4
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
-
Apr 2018 — Jun 2018 [monthly]
Completed PHASE4
-
Jan 2017 — Apr 2018 [monthly]
Completed PHASE4
First recorded
Feb 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Joseph Kuti
- Thrasher Research Fund
For direct contact, visit the study record on ClinicalTrials.gov .